Spineway Expects Normalization in the Second Half After a Slowdown in Q1 2026
The specialist in innovative implants for spinal pathologies experienced a contraction in the first quarter after six months of upward momentum. While the decline is concerning, the management emphasizes that this slowdown is due to identified external factors that are being resolved. It remains to be seen if the level of orders will indeed reinvigorate the activity from the second half of the year, as the company anticipates.
Quarterly Contraction Following Strong Growth at the End of 2025
Spineway posted a revenue of €2.2 million in the first quarter of 2026, marking a clear break from the dynamics of the fourth quarter of 2025, where the group had recorded a growth of 38%. According to the press release, this decline is due to two hurdles: delays in regulatory approvals in certain geographical areas and supply delays from subcontractors impacted by the general acceleration of activity. The group describes these difficulties as localized and in the process of being resolved.
Uneven Regional Performances and a Resilient French Market
The geography of the group reveals pronounced contrasts. In Asia, the activity confirms its solidity with a growth of 3.7%, supported by growth prospects in Vietnam and Australia. On the other hand, the Middle East remains temporarily halted in an unfavorable geopolitical context. Latin America records a decline of €0.4 million, with a more gradual ramp-up of deliveries than expected, although the region remains targeted for its high potential. In France, the domestic market remains stable, supported by prioritized stock management, while Europe experiences a slight contraction.
A High Order Book Supposed to Normalize the Situation in the Second Half
Spineway anticipates a gradual improvement in the lag between recorded orders and revenue recognition starting from the second half of 2026. This lag, attributed to the current acceleration phase, is expected to be absorbed to compensate for quarterly volatility. The group continues to intensify a multi-year approval program in a structurally supportive environment for the medical spine sector.
